Latest Breaking News On - Antoni vilaseca - Page 1 : comparemela.com

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively
cadillacnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cadillacnews.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaUnited statesSan antonioAnia diantonioRodriguez fabaSabine brookmanPrnewswire johnsonIndianj urolNone of janssen research developmentAmerican cancer societyLate development oncologyJanssen research developmentBladder cancer advocacy networkJanssen biotech incDrug administrationJanssen pharmaceuticals

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively

/PRNewswire/ Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of.

San antonioUnited statesComunidad autonoma de catalunaPrnewswire johnsonSabine brookmanRodriguez fabaAnia diantonioIndianj urolAmerican cancer societyAmerican urological associationJanssen pharmaceuticalsJanssen research developmentDrug administrationAstex pharmaceuticalsLate development oncologyEuropean association of urology

First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery system Phase 1 results show a manageable safety profile with limited systemic toxicity, and early complete responses in patients with high-risk and intermediate-risk NMIBC MADRID, Oct. 22, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & […]

Comunidad autonoma de catalunaObrian kenneyJeffrey infanteEuropean society for medical oncologyCompanies of johnsonJanssen biotech incJanssen pharmaceutical companies of johnsonTranslational researchExchange commissionOncology early clinical developmentNone of janssen research developmentJanssen research developmentJanssen pharmaceutical companiesLate breaking mini oral presentation sessionEuropean societyMedical oncology

Erdafitinib Intravesical Delivery System Under Exploration in Select FGFR+ NMIBC or MIBC

Antoni Vilaseca, MD, PhD, explains the unique mechanism of the TAR-210 erdafitinib delivery system and expands on the key objectives, trial design, and patient characteristics of a phase 1 trial evaluating TAR-210 in patients with recurrent NMIBC or MIBC harboring select FGFR mutations or fusions.

Comunidad autonoma de catalunaUrology serviceAntoni vilasecaCancers symposiumUniversitat de barcelonaBacillus calmette guerinNew methods of delivery for erdafitinibIntravesical drug delivery systemTar 210Patients with non muscle invasive bladder cancerOral delivery of erdafitinibThor 2 trialPatients with recurrent nmibc or mibc harboring select fgfr mutations fusionsHospital clínic de barcelona